Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Adaptive Biotechnologies and Genzyme Corporation.

Medical Crossfire®: How Can We Best Leverage the Use of MRD to Optimize Outcomes in the Management of Hematologic Malignancies?


Release Date: April 30, 2019
Expiration Date: April 30, 2020
Media: Internet - based

Activity Overview

This online Medical Crossfire® activity is an engaging discussion about current and future perspectives on the use of measurable (or minimal) residual disease (MRD) between experts in the treatment of hematologic malignancies. The panelists will discuss the available evidence for the predictive and prognostic role of MRD in guiding treatment decisions for patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), multiple myeloma, and chronic lymphocytic leukemia (CLL). The experts provide an overview of emerging data, and challenge each other to consider how best to apply the evidence to optimize outcomes for their patients. This discussion also includes identifying the gaps in clinical practice for the use of MRD today, and how emerging data will continue to address these gaps in the future.

Benefits of Participation

  • Learn about the current role and supporting data for the use of MRD monitoring in managing hematologic malignancies
  • Hear expert perspectives on how ongoing and upcoming clinical trials can address knowledge gaps in the use of MRD to guide treatment
  • Gain knowledge from expert responses to challenging questions regarding the integration of MRD monitoring into clinical practice

CME Activity Table of Contents

  • Pretest
  • Module 1: Introduction
  • Module 2: Medical Crossfire 1: Methods Utilized for MRD Detection: Focus on ALL
  • Module 3: Medical Crossfire 2: Assessing How MRD Should Be Used in Clinical Practice Today: Focus on AML
  • Module 4: Medical Crossfire 3: How Will MRD Be Used Tomorrow? Focus on Multiple Myeloma
  • Module 5: Medical Crossfire 4: A Look at Future Clinical Applications: Focus on CLL
  • Module 6: Key Takeaways and Closing Remarks
  • Posttest

Acknowledgement of Commercial Support

This activity is supported by educational grants from Adaptive Biotechnologies and Genzyme Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, hematologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment of hematologic malignancies.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Discuss current methodologies and approaches to detect measurable (or minimal) residual disease (MRD)
  • Evaluate the clinical utility of MRD assessment, and how it can be applied to inform treatment decisions among adolescents and adults with hematologic malignancies
  • Apply MRD findings to case-based hematologic malignancy scenarios commonly encountered in clinical practice
  • Evaluate investigations that have utilized MRD and the value of this biomarker in clinical trials

Faculty, Staff, and Planners’ Disclosures

Chair

Elias JabbourElias Jabbour, MD  
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
 
 

Disclosures: Grant Research Support: Amgen, Pfizer, Takeda, Adaptive Biotechnologies, Novartis, Spectrum, AbbVie, Bristol-Myers Squibb.

Faculty

Anthony MatoAnthony Mato, MD  
Hematologic Oncologist
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosures: Grant Research Support: TG Therapeutics, Pharmacyclics, AbbVie, Johnson and Johnson, Acerta/AZ, Regeneron, DTRM BioPharma, Sunesis, Loxo; Consultant: TG Therapeutics, Pharmacyclics, AbbVie, Johnson and Johnson, Acerta/AZ, DTRM BioPharma, Sunesis, Celgene.

Eytan M. SteinEytan M. Stein, MD  
Assistant Attending Physician
Department of Medicine
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Bayer, Agios, Celgene, Syros; Consultant/Advisory Board: Bayer, Agios, Celgene, Syros, Pfizer, Novartis, Daiichi Sankyo, Astellas, Biolinene.

Urvi A. ShahUrvi A. Shah, MD  
Assistant Attending Physician
Department of Medicine
Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: No relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By